Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

Aims Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile [...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure 2022-12, Vol.9 (6), p.3791-3803
Main Authors: Senni, Michele, Lopez‐Sendon, Jose, Cohen‐Solal, Alain, Ponikowski, Piotr, Nkulikiyinka, Richard, Freitas, Cecilia, Vlajnic, Vanja Miodrag, Roessig, Lothar, Pieske, Burkert
Format: Article
Language:English
Subjects:
Body mass index
Cardiac arrhythmia
Cardiology and cardiovascular system
Ejection fraction
Heart failure
Heart Failure - drug therapy
Heart failure with reduced ejection fraction
Hospitalization
Human health and pathology
Humans
Laboratories
Life Sciences
Natriuretic Peptide, Brain
NT‐proBNP
Patients
Peptides
Stroke Volume - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile [Q4]. Methods and results VICTORIA participants with available baseline NT‐proBNP levels (n = 4805; 95.1% of total) were included. Compared with patients in Q1–Q3 (NT‐proBNP: Q1, ≤1556 pg/mL; Q2, >1556–2816 pg/mL; and Q3, >2816–5314 pg/mL), patients in Q4 (NT‐proBNP: >5314 pg/mL) were older (69.2 ± 12.0 vs. 66.6 ± 12.1 years), had lower mean ejection fraction (27.2 ± 8.3% vs. 29.5 ± 8.2%; P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.14050